In summary, our ultrasomic model performed well in noninvasively predicting the efficacy of TKI plus anti-PD-1 therapy in HCC, providing an important tool for non-invasively assessing the tumor microenvironment. Here, PDCD1 is linked to hepatocellular carcinoma.